SIGA Reports Financial Results for Three Months Ended March 31, 2022
May 05, 2022 16:05 ET
|
SIGA Technologies Inc.
- First Sale of Intravenous (IV) TPOXX® to U.S. Government under the 19C BARDA Contract – - Contract with a New International Jurisdiction for an Initial Order of Approximately $3 Million of Oral...
SIGA Declares Special Dividend of $0.45 Per Share
May 05, 2022 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the Board of Directors declared a special...
SIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial Results
April 28, 2022 16:05 ET
|
SIGA Technologies Inc.
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021
March 03, 2022 16:05 ET
|
SIGA Technologies Inc.
- Approximately $113 Million of U.S. Product Sales in 2021 – - Approximately $13 Million of International Product Sales in 2021 – - Corporate Update Conference Call Today at 4:30...
SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials
March 02, 2022 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it...
SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial Results
February 24, 2022 10:27 ET
|
SIGA Technologies Inc.
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...
SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech
January 25, 2022 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it...
SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
January 18, 2022 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, announced today that it...
SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat
January 10, 2022 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the...
SIGA Announces Health Canada Regulatory Approval of Oral TPOXX®
December 01, 2021 09:55 ET
|
SIGA Technologies Inc.
NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that...